Women navigating perimenopause and menopause are already spending on products and services sold for long-term health. Many still say those offerings fall short. Boston Consulting Group (BCG) has put a striking figure on the potential market: $350 billion. It is an estimate of additional spending that might occur if better options existed, not money that has been lost or a measure of improved health.
In a September 22 report prepared for the St. Moritz Longevity Forum, BCG describes a survey of 10,608 respondents in 12 countries: Brazil, China, France, Germany, India, Japan, Qatar, Saudi Arabia, Switzerland, the United Arab Emirates, the United Kingdom and the United States. The report explores how people define and buy “longevity” interventions, a broad category spanning consumables, services and specialized treatments.
What the survey found
After adjusting for age, BCG reports that women in perimenopause or menopause had tried interventions at rates 15 to 22 percentage points higher than other women or men. They had tried an average of 3.3 more interventions than women in other life stages and 2.9 more than men. Yet satisfaction was around 50% across the groups, according to BCG. Trying more products did not translate into greater reported satisfaction.
The group’s median reported spending on longevity was $84 a month, compared with $68 for other women and $73 for men. About a third of women in the menopause transition said they would spend more if a suitable product or service existed. BCG reports a median additional willingness to spend of $108 a month among those respondents.
Those answers describe consumer behavior and stated preferences. They do not establish that the purchased interventions work, improve healthspan or extend life. “Longevity” is a marketing and survey category here, not a clinical outcome.
How BCG gets to $350 billion
BCG applies the survey’s willingness-to-spend finding to an estimated global population of one billion women in menopause whom it describes as actively engaged in longevity spending. That extrapolation produces its $350 billion incremental market opportunity. The estimate depends on how many people are in the addressable group, how stated willingness translates into actual purchases, and whether offerings meet needs at a price people will pay.
The report does not demonstrate $350 billion in current sales, an annual reduction in medical costs, or a quantified benefit from any treatment. A survey across 12 countries also cannot by itself show that purchasing behavior would be identical in every market. The report’s commercial framing is useful for understanding investment interest, but its projection should be read as a scenario, not a measured global shortfall.
The care gap behind the market pitch
BCG also reports that 63% of surveyed women consulted a doctor about hormone-related issues such as polycystic ovary syndrome, endometriosis or menopause, versus 78% for cardiovascular concerns. Among those who sought care, 72% said they felt taken seriously for hormone-related issues, compared with 85% for heart-related symptoms. These are self-reported survey responses, but they point to a concern beyond consumer products: whether appropriate care is accessible and responsive.
The report says women in the menopause transition want evidence-backed options recommended by trusted clinicians, with better value, fewer side effects and insurance coverage. Those preferences are a stronger editorial signal than the market total. More products labelled “longevity” would not necessarily address symptoms, chronic disease risk or the gaps in clinical care.
What to watch next
For companies, the survey suggests a large, engaged audience dissatisfied with current offerings. For patients and clinicians, the meaningful test is whether new services improve access, symptom management or measurable health outcomes. Research should distinguish proven care from products that borrow longevity language without evidence.
BCG’s $350 billion figure may attract investment, but it cannot tell us which intervention works. The opportunity worth tracking is whether that investment produces useful, tested care for women through midlife and beyond.
Source and reporting note
Primary source: BCG, The $350 Billion Longevity Mismatch in Women’s Health, September 22, 2026. Survey results and the market estimate are attributed to BCG. The distinctions between stated demand, realized spending and clinical benefit are The Lifespan Brief’s analysis. Featured image is an original conceptual illustration, not a depiction of survey participants.